Literature DB >> 22896617

Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys.

Kathryn E Stephenson1, Adam SanMiguel, Nathaniel L Simmons, Kaitlin Smith, Mark G Lewis, James J Szinger, Bette Korber, Dan H Barouch.   

Abstract

A global HIV-1 vaccine will likely need to induce immune responses against conserved HIV-1 regions to contend with the profound genetic diversity of HIV-1. Here we evaluated the capacity of immunogens consisting of only highly conserved HIV-1 sequences that are aimed at focusing cellular immune responses on these potentially critical regions. We assessed in rhesus monkeys the breadth and magnitude of T lymphocyte responses elicited by adenovirus vectors expressing either full-length HIV-1 Gag/Pol/Env immunogens or concatenated immunogens consisting of only highly conserved HIV-1 sequences. Surprisingly, we found that the full-length immunogens induced comparable breadth (P = 1.0) and greater magnitude (P = 0.01) of CD8(+) T lymphocyte responses against conserved HIV-1 regions compared with the conserved-region-only immunogens. Moreover, the full-length immunogens induced a 5-fold increased total breadth of HIV-1-specific T lymphocyte responses compared with the conserved-region-only immunogens (P = 0.007). These results suggest that full-length HIV-1 immunogens elicit a substantially increased magnitude and breadth of cellular immune responses compared with conserved-region-only HIV-1 immunogens, including greater magnitude and comparable breadth of responses against conserved sequences.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22896617      PMCID: PMC3486282          DOI: 10.1128/JVI.01779-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Authors:  Barton F Haynes; Peter B Gilbert; M Juliana McElrath; Susan Zolla-Pazner; Georgia D Tomaras; S Munir Alam; David T Evans; David C Montefiori; Chitraporn Karnasuta; Ruengpueng Sutthent; Hua-Xin Liao; Anthony L DeVico; George K Lewis; Constance Williams; Abraham Pinter; Youyi Fong; Holly Janes; Allan DeCamp; Yunda Huang; Mangala Rao; Erik Billings; Nicos Karasavvas; Merlin L Robb; Viseth Ngauy; Mark S de Souza; Robert Paris; Guido Ferrari; Robert T Bailer; Kelly A Soderberg; Charla Andrews; Phillip W Berman; Nicole Frahm; Stephen C De Rosa; Michael D Alpert; Nicole L Yates; Xiaoying Shen; Richard A Koup; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Nelson L Michael; Jerome H Kim
Journal:  N Engl J Med       Date:  2012-04-05       Impact factor: 91.245

2.  Mosaic HIV-1 Gag antigens can be processed and presented to human HIV-specific CD8+ T cells.

Authors:  Zaza M Ndhlovu; Alicja Piechocka-Trocha; Seanna Vine; Ashley McMullen; Kegakilwe C Koofhethile; Phillip J R Goulder; Thumbi Ndung'u; Dan H Barouch; Bruce D Walker
Journal:  J Immunol       Date:  2011-05-16       Impact factor: 5.422

3.  DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults.

Authors:  Geoffrey J Gorse; Mark J Newman; Allan deCamp; Christine Mhorag Hay; Stephen C De Rosa; Elizabeth Noonan; Brian D Livingston; Jonathan D Fuchs; Spyros A Kalams; Farah L Cassis-Ghavami
Journal:  Clin Vaccine Immunol       Date:  2012-03-07

4.  Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.

Authors:  Maximillian Rosario; Anne Bridgeman; Esther D Quakkelaar; Maire F Quigley; Brenna J Hill; Maria L Knudsen; Virginia Ammendola; Karl Ljungberg; Nicola Borthwick; Eung-Jun Im; Andrew J McMichael; Jan W Drijfhout; Hui Yee Greenaway; Vanessa Venturi; Daniel C Douek; Stefano Colloca; Peter Liljeström; Alfredo Nicosia; David A Price; Cornelis J M Melief; Tomás Hanke
Journal:  Eur J Immunol       Date:  2010-07       Impact factor: 5.532

5.  Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques.

Authors:  Maximillian Rosario; Nicola Borthwick; Guillaume B Stewart-Jones; Alice Mbewe-Mvula; Anne Bridgeman; Stefano Colloca; David Montefiori; Andrew J McMichael; Alfredo Nicosia; Esther D Quakkelaar; Jan W Drijfhout; Cornelis J M Melief; Tomáš Hanke
Journal:  AIDS       Date:  2012-01-28       Impact factor: 4.177

6.  Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys.

Authors:  Dan H Barouch; Kara L O'Brien; Nathaniel L Simmons; Sharon L King; Peter Abbink; Lori F Maxfield; Ying-Hua Sun; Annalena La Porte; Ambryice M Riggs; Diana M Lynch; Sarah L Clark; Katherine Backus; James R Perry; Michael S Seaman; Angela Carville; Keith G Mansfield; James J Szinger; Will Fischer; Mark Muldoon; Bette Korber
Journal:  Nat Med       Date:  2010-02-21       Impact factor: 53.440

7.  Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study.

Authors:  Fusheng Li; Adam C Finnefrock; Sheri A Dubey; Bette T M Korber; James Szinger; Suzanne Cole; M Juliana McElrath; John W Shiver; Danilo R Casimiro; Lawrence Corey; Steven G Self
Journal:  PLoS One       Date:  2011-06-10       Impact factor: 3.240

8.  Definition of the viral targets of protective HIV-1-specific T cell responses.

Authors:  Beatriz Mothe; Anuska Llano; Javier Ibarrondo; Marcus Daniels; Cristina Miranda; Jennifer Zamarreño; Vanessa Bach; Rosario Zuniga; Susana Pérez-Álvarez; Christoph T Berger; Maria C Puertas; Javier Martinez-Picado; Morgane Rolland; Marilu Farfan; James J Szinger; William H Hildebrand; Otto O Yang; Victor Sanchez-Merino; Chanson J Brumme; Zabrina L Brumme; David Heckerman; Todd M Allen; James I Mullins; Guadalupe Gómez; Philip J Goulder; Bruce D Walker; Jose M Gatell; Bonaventura Clotet; Bette T Korber; Jorge Sanchez; Christian Brander
Journal:  J Transl Med       Date:  2011-12-07       Impact factor: 5.531

9.  Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.

Authors:  Dan H Barouch; Jinyan Liu; Hualin Li; Lori F Maxfield; Peter Abbink; Diana M Lynch; M Justin Iampietro; Adam SanMiguel; Michael S Seaman; Guido Ferrari; Donald N Forthal; Ilnour Ourmanov; Vanessa M Hirsch; Angela Carville; Keith G Mansfield; Donald Stablein; Maria G Pau; Hanneke Schuitemaker; Jerald C Sadoff; Erik A Billings; Mangala Rao; Merlin L Robb; Jerome H Kim; Mary A Marovich; Jaap Goudsmit; Nelson L Michael
Journal:  Nature       Date:  2012-01-04       Impact factor: 49.962

10.  Candidate vaccine sequences to represent intra- and inter-clade HIV-1 variation.

Authors:  Otto O Yang
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240

View more
  33 in total

1.  Short conserved sequences of HIV-1 are highly immunogenic and shift immunodominance.

Authors:  Otto O Yang; Ayub Ali; Noriyuki Kasahara; Emmanuelle Faure-Kumar; Jin Young Bae; Louis J Picker; Haesun Park
Journal:  J Virol       Date:  2014-11-05       Impact factor: 5.103

2.  DNA Prime-Boost Vaccine Regimen To Increase Breadth, Magnitude, and Cytotoxicity of the Cellular Immune Responses to Subdominant Gag Epitopes of Simian Immunodeficiency Virus and HIV.

Authors:  Xintao Hu; Antonio Valentin; Frances Dayton; Viraj Kulkarni; Candido Alicea; Margherita Rosati; Bhabadeb Chowdhury; Rajeev Gautam; Kate E Broderick; Niranjan Y Sardesai; Malcolm A Martin; James I Mullins; George N Pavlakis; Barbara K Felber
Journal:  J Immunol       Date:  2016-10-12       Impact factor: 5.422

Review 3.  HIV-1 vaccines: challenges and new perspectives.

Authors:  Jean-Louis Excler; Merlin L Robb; Jerome H Kim
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

4.  Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer.

Authors:  Joseph P Nkolola; Christine A Bricault; Ann Cheung; Jennifer Shields; James Perry; James M Kovacs; Elena Giorgi; Margot van Winsen; Adrian Apetri; Els C M Brinkman-van der Linden; Bing Chen; Bette Korber; Michael S Seaman; Dan H Barouch
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

5.  Characterization of T-cell responses to cryptic epitopes in recipients of a noncodon-optimized HIV-1 vaccine.

Authors:  Anne Bet; Sarah Sterrett; Alicia Sato; Anju Bansal; Paul A Goepfert
Journal:  J Acquir Immune Defic Syndr       Date:  2014-02-01       Impact factor: 3.731

Review 6.  Progress in HIV-1 vaccine development.

Authors:  Barton F Haynes; M Juliana McElrath
Journal:  Curr Opin HIV AIDS       Date:  2013-07       Impact factor: 4.283

7.  Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development.

Authors:  Kathryn E Stephenson; George H Neubauer; Ulf Reimer; Nikolaus Pawlowski; Tobias Knaute; Johannes Zerweck; Bette T Korber; Dan H Barouch
Journal:  J Immunol Methods       Date:  2014-11-15       Impact factor: 2.303

Review 8.  New concepts in HIV-1 vaccine development.

Authors:  Kathryn E Stephenson; Helen T D'Couto; Dan H Barouch
Journal:  Curr Opin Immunol       Date:  2016-06-03       Impact factor: 7.486

9.  Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys.

Authors:  Dan H Barouch; Kathryn E Stephenson; Erica N Borducchi; Kaitlin Smith; Kelly Stanley; Anna G McNally; Jinyan Liu; Peter Abbink; Lori F Maxfield; Michael S Seaman; Anne-Sophie Dugast; Galit Alter; Melissa Ferguson; Wenjun Li; Patricia L Earl; Bernard Moss; Elena E Giorgi; James J Szinger; Leigh Anne Eller; Erik A Billings; Mangala Rao; Sodsai Tovanabutra; Eric Sanders-Buell; Mo Weijtens; Maria G Pau; Hanneke Schuitemaker; Merlin L Robb; Jerome H Kim; Bette T Korber; Nelson L Michael
Journal:  Cell       Date:  2013-10-24       Impact factor: 41.582

10.  Vaccines that stimulate T cell immunity to HIV-1: the next step.

Authors:  Andrew J McMichael; Wayne C Koff
Journal:  Nat Immunol       Date:  2014-04       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.